Anavex to Present at Biotech Showcase 2015 in San Francisco

Anavex Begins Enrollment of Alzheimer’s Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

Anavex Upgrades to OTCQX Marketplace

Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for the Treatment of Alzheimer’s

Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference

Anavex to Present at SeeThruEquity Investor Conference in New York City

Anavex Receives Regulatory Approval to Initiate Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS for Alzheimer’s disease

Institutional Investor Lincoln Park Capital Increases Ownership in Anavex, Pays Over 25% Premium to Market

Anavex Supports Alzheimer’s Foundation of America’s 3rd Annual Concepts in Care Educational Conference

Anavex to Present at Rodman & Renshaw 16th Annual Global Investment Conference